A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730357 Administered as Oral Solution and Tablets to Healthy Subjects, and a Randomized, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 730357 as Tablet Versus Oral Solution and Tablet With and Without Food
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2017
At a glance
- Drugs BI 730357 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 25 Jul 2017 Planned End Date changed from 3 Aug 2017 to 17 Aug 2017.
- 25 Jul 2017 Planned primary completion date changed from 3 Aug 2017 to 17 Aug 2017.
- 19 Jun 2017 Planned number of patients changed from 68 to 84.